Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
cancer vaccine
Biotech
Pfizer punts pair of orphan drugs amid rare disease R&D rethink
Pfizer dropped the drugs in a pipeline cull that also narrowed the opportunities open to the near-approval JAK3/TEC inhibitor ritlecitinib.
Nick Paul Taylor
Jan 31, 2023 9:15am
Have mRNA cancer vaccines arrived? Biopharma execs weigh in
Jan 25, 2023 10:30am
Cancer vaccine-focused Elicio uses Angion as path to Nasdaq
Jan 17, 2023 8:45am
'We don't know' what the limits are for RNA therapies
Jan 9, 2023 6:00am
BioNTech's UK gov pact to get cancer therapies to 10K patients
Jan 6, 2023 12:29pm
Y-Mabs drops 3rd of staff, cancer vaccine ambitions
Jan 5, 2023 8:40am